Last reviewed · How we verify
Rilpivirine (RPV) LA
Rilpivirine (RPV) LA is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of HIV-1.
Rilpivirine (RPV) LA is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of HIV-1. Used for Treatment of HIV-1 infection in adults and adolescents.
At a glance
| Generic name | Rilpivirine (RPV) LA |
|---|---|
| Also known as | Rekambys |
| Sponsor | ViiV Healthcare |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV-1 reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
By binding to the HIV-1 reverse transcriptase enzyme, RPV LA prevents the virus from replicating and reduces the viral load in the body. This mechanism of action is specific to HIV-1 and does not affect other viruses or cellular processes.
Approved indications
- Treatment of HIV-1 infection in adults and adolescents
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Insomnia
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (PHASE3)
- Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units". (NA)
- Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (PHASE2)
- More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (PHASE1, PHASE2)
- Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rilpivirine (RPV) LA CI brief — competitive landscape report
- Rilpivirine (RPV) LA updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI